PROSTAGLANDINS AND CANCER
Top Cited Papers
Open Access
- 1 January 2006
- Vol. 55 (1), 115-122
- https://doi.org/10.1136/gut.2004.047100
Abstract
The most effective treatments for cancer, including various combinations of surgical resection, radiation, and/or chemotherapy, depend on the detection of cancer at a very early stage. Unfortunately, it has not been possible to identify all individuals who are at the highest risk for developing cancer. Most patients present to their physician with advanced cancer when standard treatment regimens for solid malignancies result in a much lower five year survival. It is generally agreed that an effective way to control cancer is to find better ways of preventing it. Chemopreventive approaches are definitely worth considering for healthy persons who have a strong family history of cancer or those who are particularly susceptible for other reasons. One promising group of compounds with cancer preventive activity includes NSAIDS.Keywords
This publication has 113 references indexed in Scilit:
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialThe New England Journal of Medicine, 2005
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionThe New England Journal of Medicine, 2005
- Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac SurgeryThe New England Journal of Medicine, 2005
- Prostaglandin E2 Regulates the Complement Inhibitor CD55/Decay-accelerating Factor in Colorectal CancerPublished by Elsevier BV ,2005
- 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-β-induced suppressor of human gastrointestinal cancersProceedings of the National Academy of Sciences of the United States of America, 2004
- Prostaglandin E2 inhibits production of the inflammatory chemokines CCL3 and CCL4 in dendritic cellsJournal of Leukocyte Biology, 2003
- PGE2 Stimulates VEGF Expression in Endothelial Cells via ERK2/JNK1 Signaling PathwaysBiochemical and Biophysical Research Communications, 2001
- The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous PolyposisThe New England Journal of Medicine, 2000
- Basic Fibroblast Growth Factor Induces Cyclooxygenase-2 Expression in Endothelial Cells Derived from BoneBiochemical and Biophysical Research Communications, 1999
- Studies of prostaglandins and sulphasalazine in ulcerative colitisProstaglandins and Medicine, 1981